Search results for "Neovascularization"

showing 10 items of 351 documents

Searching for the right timing of surgical delay: angiogenesis, vascular endothelial growth factor and perfusion changes in a skin-flap model.

2009

Summary Background The angiogenic potential of vascular endothelial growth factor (VEGF) and its oxygen pressure-dependent regulation suggest a strong connection between this growth factor and the ‘delay phenomenon'. In this study we focused on the chronological changes in VEGF concentration and flap perfusion in order to optimise the duration of surgical delay. Methods The VEGF concentration in skin and underlying muscle was measured in oversized, random-pattern flaps on 38 male Sprague-Dawley rats after 3, 5 or 7 days of surgical delay. Additionally, flaps were raised 5 or 7 days past preconditioning. The effect on flap perfusion was measured using indocyanine green fluoroscopy and the si…

CD31Graft RejectionMalemedicine.medical_specialtyTime FactorsAngiogenesismedicine.medical_treatmentNeovascularization PhysiologicVasodilationEnzyme-Linked Immunosorbent AssayStatistics NonparametricSurgical FlapsNeovascularizationRats Sprague-Dawleychemistry.chemical_compoundRandom AllocationLaser-Doppler FlowmetryMedicineAnimalsProbabilitySkinbusiness.industryVascular Endothelial Growth FactorsGrowth factorMicrocirculationGraft SurvivalSkin TransplantationSurgeryRatsVascular endothelial growth factorDisease Models AnimalchemistryMultivariate AnalysisSurgerymedicine.symptombusinessIndocyanine greenPerfusionBiomarkersJournal of plastic, reconstructiveaesthetic surgery : JPRAS
researchProduct

Implanted neonatal human dermal fibroblasts influence the recruitment of endothelial cells in mice

2012

The vascularization of new tissue within a reasonable time is a crucial prerequisite for the success of different cell- and material-based strategies. Considering that angiogenesis is a multi-step process involving humoral and cellular regulatory components, only in vivo assays provide the adequate information about vessel formation and the recruitment of endothelial cells. The present study aimed to investigate if neonatal human dermal fibroblasts could influence in vivo neovascularization. Results obtained showed that fibroblasts were able to recruit endothelial cells to vascularize the implanted matrix, which was further colonized by murine functional blood vessels after one week. The ve…

CD31MalePathologymedicine.medical_specialtyAngiogenesisCell TransplantationBiomedical EngineeringCD34Medicine (miscellaneous)Neovascularization PhysiologicInflammationAntigens CD34BiologyNitric OxideRegenerative MedicineBiomaterialsNeovascularizationHemoglobinsMiceTissue engineeringMicroscopy Electron TransmissionIn vivoReportmedicineAnimalsHumansRegenerationSkinInflammationMatrigelNeovascularization PathologicTissue EngineeringEndothelial CellsGeneral MedicineFibroblastsMice Inbred C57BLPlatelet Endothelial Cell Adhesion Molecule-1Drug CombinationsPhenotypeProteoglycansCollagenLamininmedicine.symptom
researchProduct

The effect of human osteoblasts on proliferation and neo-vessel formation of human umbilical vein endothelial cells in a long-term 3D co-culture on p…

2008

Angiogenesis is a key element in early wound healing and is considered important for tissue regeneration and for directing inflammatory cells to the wound site. The improvement of vascularization by implementation of endothelial cells or angiogenic growth factors may represent a key solution for engineering bone constructs of large size. In this study, we describe a long-term culture environment that supports the survival, proliferation, and in vitro vasculogenesis of human umbilical vein endothelial cells (HUVEC). This condition can be achieved in a co-culture model of HUVEC and primary human osteoblasts (hOB) employing polyurethane scaffolds and platelet-rich plasma in a static microenvir…

CD31Umbilical VeinsTime FactorsMaterials scienceAngiogenesisCellular differentiationPolyurethanesBiophysicsFluorescent Antibody TechniqueNeovascularization PhysiologicBioengineeringUmbilical veinBiomaterialsVasculogenesismedicineHumansCells CulturedCell ProliferationMicroscopy ConfocalOsteoblastsTissue ScaffoldsReverse Transcriptase Polymerase Chain ReactionEndothelial CellsOsteoblastCoculture TechniquesCell biologyEndothelial stem cellPhenotypemedicine.anatomical_structureGene Expression RegulationMechanics of MaterialsImmunologycardiovascular systemCeramics and CompositesWound healingBiomarkersBiomaterials
researchProduct

Impaired in vivo vasculogenic potential of endothelial progenitor cells in comparison to human umbilical vein endothelial cells in a spheroid-based i…

2009

Objectives:  Neovascularization represents a major challenge in tissue engineering applications since implantation of voluminous grafts without sufficient vascularity results in hypoxic cell death of implanted cells. An attractive therapeutic approach to overcome this is based on co-implantation of endothelial cells to create vascular networks. We have investigated the potential of human endothelial progenitor cells (EPC) to form functional blood vessels in vivo in direct comparison to vascular-derived endothelial cells, represented by human umbilical vein endothelial cells (HUVEC). Materials and methods:  EPCs were isolated from human peripheral blood, expanded in vitro and analysed in vit…

CD31Umbilical VeinsTransplantation HeterologousNeovascularization PhysiologicMice SCIDBiologyUmbilical veinNeovascularizationMiceVasculogenesisTissue engineeringSpheroids CellularmedicineAnimalsHumansProgenitor cellCells CulturedMatrigelTissue EngineeringStem CellsEndothelial CellsCell BiologyGeneral MedicineOriginal ArticlesCell biologyTransplantationPhenotypeImmunologyembryonic structurescardiovascular systemmedicine.symptomStem Cell TransplantationCell proliferation
researchProduct

An injectable bone substitute composed of beta-tricalcium phosphate granules, methylcellulose and hyaluronic acid inhibits connective tissue influx i…

2011

In this study, the in vivo tissue reaction to a new triphasic and injectable paste-like bone-substitute material composed of beta-tricalcium phosphate (β-TCP), methylcellulose and hyaluronic acid was analyzed. Using a subcutaneous implantation model, the interaction of these materials and the peri-implant tissue reaction were tested in Wistar rats for up to 60 days by means of established histological methods, including histomorphometrical analysis. The study focused on tissue integration, classification of the cellular inflammatory response and the degradation of the material. Groups composed of animals injected only with β-TCP granules, sham-operated animals and animals injected with sali…

Calcium PhosphatesBone RegenerationTime FactorsMaterials sciencemedicine.medical_treatmentBiomedical EngineeringNeovascularization PhysiologicConnective tissueMethylcelluloseBiochemistryBiomaterialsNeovascularizationchemistry.chemical_compoundCell MovementIn vivoMaterials TestingHyaluronic acidmedicineAnimalsHyaluronic AcidRats WistarMolecular BiologySalinePhagocytesGranule (cell biology)General MedicinePhosphateRatsmedicine.anatomical_structurechemistryBone SubstitutesImplantmedicine.symptomBiotechnologyBiomedical engineeringActa Biomaterialia
researchProduct

Collagen-embedded hydroxylapatite–beta-tricalcium phosphate–silicon dioxide bone substitute granules assist rapid vascularization and promote cell gr…

2010

In the present study we assessed the biocompatibility in vitro and in vivo of a low-temperature sol-gel-manufactured SiO(2)-based bone graft substitute. Human primary osteoblasts and the osteoblastic cell line, MG63, cultured on the SiO(2) biomatrix in monoculture retained their osteoblastic morphology and cellular functionality in vitro. The effect of the biomaterial in vivo and its vascularization potential was tested subcutaneously in Wistar rats and demonstrated both rapid vascularization and good integration within the peri-implant tissue. Scaffold degradation was progressive during the first month after implantation, with tartrate-resistant acid phosphatase-positive macrophages being …

Calcium PhosphatesScaffoldMaterials scienceBiocompatibilityBiomedical EngineeringNeovascularization PhysiologicBioengineeringCell LineBiomaterialschemistry.chemical_compoundVasculogenesisIn vivoMaterials TestingHumansCell ProliferationOsteoblastsCell growthBiomaterialHydroxylapatiteSilicon DioxideIn vitroCell biologychemistryBone SubstitutesBlood VesselsCollagenBiomedical engineeringBiomedical Materials
researchProduct

Influence of β-tricalcium phosphate granule size and morphology on tissue reaction in vivo.

2010

In this study the tissue reaction to five different β-tricalcium phosphate (β-TCP)-based bone substitute materials differing only in size, shape and porosity was analyzed over 60 days, at 3, 10, 15, 30 and 60 days after implantation. Using the subcutaneous implantation model in Wistar rats both the inflammatory response within the implantation bed and the resulting vascularization of the biomaterials were qualitatively and quantitatively assessed by means of standard and special histological staining methods. The data from this study showed that all investigated β-TCP bone substitutes induced the formation of multinucleated giant cells. Changes in size, shape and porosity influenced the int…

Calcium PhosphatesVascular Endothelial Growth Factor AChemokineMaterials scienceCellBiomedical EngineeringNeovascularization PhysiologicBiocompatible MaterialsBiochemistryGiant CellsBiomaterialschemistry.chemical_compoundImplants ExperimentalX-Ray DiffractionIn vivomedicineAnimalsParticle SizeRats WistarMolecular BiologybiologyGranule (cell biology)Acid phosphataseBiomaterialGeneral MedicineAnatomyImmunohistochemistryRatsVascular endothelial growth factormedicine.anatomical_structurechemistryGiant cellOrgan SpecificityBone Substitutesbiology.proteinBiophysicsMicroscopy Electron ScanningBiotechnologyActa biomaterialia
researchProduct

Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis

2012

The present study is designed to assess if exosomes released from Chronic Myelogenous Leukemia (CML) cells may modulate angiogenesis. We have isolated and characterized the exosomes generated from LAMA84 CML cells and demonstrated that addition of exosomes to human vascular endothelial cells (HUVEC) induces an increase of both ICAM-1 and VCAM-1 cell adhesion molecules and interleukin-8 expression. The stimulation of cell-cell adhesion molecules was paralleled by a dose-dependent increase of adhesion of CML cells to a HUVEC monolayer. We further showed that the treatment with exosomes from CML cells caused an increase in endothelial cell motility accompanied by a loss of VE-cadherin and β-ca…

Cancer ResearchAngiogenesisVascular Cell Adhesion Molecule-1BiologyExosomesArticleExosomes Chronic Myelogenous Leukemia Cells Endothelial cells Tumor MicroenvironmentMiceAntigens CDCell Movementhemic and lymphatic diseasesCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositivemedicineCell AdhesionHuman Umbilical Vein Endothelial CellsTumor MicroenvironmentAnimalsHumansCell adhesionbeta CateninMatrigelTumor microenvironmentNeovascularization PathologicCell adhesion moleculeInterleukin-8medicine.diseaseCadherinsIntercellular Adhesion Molecule-1MicrovesiclesCell biologyEndothelial stem cellDrug CombinationsOncologyGene Expression RegulationCancer researchProteoglycansCollagenLamininChronic myelogenous leukemia
researchProduct

Tumor Hypoxia: Causative Factors, Compensatory Mechanisms, and Cellular Response

2004

Abstract Learning Objectives After completing this course, the reader will be able to: Explain the effect of hypoxia on resistance to treatment. Describe the causes of tumor hypoxia. Characterize cellular response to hypoxia. Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com Hypoxia is a characteristic feature of locally advanced solid tumors resulting from an imbalance between oxygen (O2) supply and consumption. Major causative factors of tumor hypoxia are abnormal structure and function of the microvessels supplying the tumor, increased diffusion distances between the nutritive blood vessels and the tumor cells, and reduced O2 tra…

Cancer ResearchCell SurvivalAnemiamedicine.medical_treatmentPhotodynamic therapyDiseaseNeoplasmsmedicineHumansNeovascularization PathologicTumor hypoxiabusiness.industryAnemiaTumor OxygenationHypoxia (medical)medicine.diseaseAdaptation PhysiologicalCell HypoxiaOxygenRadiation therapyCell Transformation NeoplasticOncologyDrug Resistance NeoplasmImmunologyDisease ProgressionCancer researchHemoglobinmedicine.symptombusinessThe Oncologist
researchProduct

Bortezomib: a new pro-apoptotic agent in cancer treatment.

2010

Bortezomib is a proteasome inhibitor. It targets the ubiquitin-proteasome pathway with subsequent inhibition of the degradation of proteins involved in cell cycle regulation and cancer cell survival. The best known molecular mechanism concerns the inhibition of IkappaB breakdown and the related stabilization of NFkappaB, thus preventing its translocation to the nucleus for the activation of downstream pathways. Bortezomib is the only drug in this class which has been approved for clinical use. It has shown an efficient antitumor effect in a phase III clinical trial (APEX) involving relapsed multiple myeloma patients. Response rate, time to progression and overall survival have been improved…

Cancer ResearchCell cycle checkpointSettore MED/06 - Oncologia MedicaAntineoplastic AgentsApoptosisPharmacologyDexamethasoneBortezomibMiceNeoplasmshemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsDrug DiscoverymedicineAnimalsHumansDexamethasoneMultiple myelomaPharmacologyproteasome inhibitionClinical Trials as TopicNeovascularization Pathologicbusiness.industryBortezomibCell CycleNF-kappa Bsolid tumorsmedicine.diseaseBoronic AcidsClinical trialBortezomib; solid tumors; proteasome inhibition.OncologyApoptosisPyrazinesCancer cellProteasome inhibitorCancer researchMultiple MyelomabusinessProteasome InhibitorsBortezomib solid tumors proteasome inhibitionmedicine.drug
researchProduct